Ruth A. Duffy

2.6k total citations · 1 hit paper
60 papers, 1.9k citations indexed

About

Ruth A. Duffy is a scholar working on Molecular Biology, Cellular and Molecular Neuroscience and Psychiatry and Mental health. According to data from OpenAlex, Ruth A. Duffy has authored 60 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 38 papers in Molecular Biology, 33 papers in Cellular and Molecular Neuroscience and 13 papers in Psychiatry and Mental health. Recurrent topics in Ruth A. Duffy's work include Receptor Mechanisms and Signaling (36 papers), Neuropeptides and Animal Physiology (21 papers) and Pharmacological Receptor Mechanisms and Effects (12 papers). Ruth A. Duffy is often cited by papers focused on Receptor Mechanisms and Signaling (36 papers), Neuropeptides and Animal Physiology (21 papers) and Pharmacological Receptor Mechanisms and Effects (12 papers). Ruth A. Duffy collaborates with scholars based in United States, United Kingdom and Denmark. Ruth A. Duffy's co-authors include Jean E. Lachowicz, Anna Eramo, Myrlene Sanon Aigbogun, Steve Offord, Cynthia A. Morgan, Geoffrey B. Varty, Siddhesh Kamat, Robert D. McQuade, Susan N. Legacy and Martin Cloutier and has published in prestigious journals such as Journal of Medicinal Chemistry, Journal of Neurochemistry and Journal of Pharmacology and Experimental Therapeutics.

In The Last Decade

Ruth A. Duffy

60 papers receiving 1.8k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The Economic Burden of Schizophrenia in the United States in 2013

2016 358 citations Martin Cloutier, Myrlene Sanon Aigbogun et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ruth A. Duffy United States	26	568	558	495	386	186	60	1.9k
Thomas Nickel Germany	27	290 0.5×	387 0.7×	275 0.6×	262 0.7×	228 1.2×	59	3.4k
Andrew P. Owens United Kingdom	21	282 0.5×	403 0.7×	351 0.7×	327 0.8×	48 0.3×	52	1.5k
Keizo Yoshida Japan	30	616 1.1×	640 1.1×	593 1.2×	420 1.1×	165 0.9×	121	2.9k
Alessandro Colasanti United Kingdom	27	635 1.1×	496 0.9×	923 1.9×	323 0.8×	936 5.0×	67	3.0k
Erling T. Mellerup Denmark	29	901 1.6×	668 1.2×	975 2.0×	101 0.3×	163 0.9×	121	2.7k
Ruth Kohen United States	22	161 0.3×	560 1.0×	687 1.4×	99 0.3×	106 0.6×	40	1.6k
Paweł Mierzejewski Poland	23	193 0.3×	447 0.8×	541 1.1×	138 0.4×	73 0.4×	95	1.4k
Ross J. Baldessarini United States	21	1.4k 2.5×	324 0.6×	481 1.0×	103 0.3×	397 2.1×	27	2.3k
Yuly Bersudsky Israel	27	916 1.6×	390 0.7×	317 0.6×	54 0.1×	154 0.8×	89	1.8k
Aron D. Mosnaim United States	20	294 0.5×	351 0.6×	378 0.8×	101 0.3×	139 0.7×	85	1.3k

Countries citing papers authored by Ruth A. Duffy

Since Specialization

Citations

This map shows the geographic impact of Ruth A. Duffy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ruth A. Duffy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ruth A. Duffy more than expected).

Fields of papers citing papers by Ruth A. Duffy

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ruth A. Duffy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ruth A. Duffy. The network helps show where Ruth A. Duffy may publish in the future.

Co-authorship network of co-authors of Ruth A. Duffy

This figure shows the co-authorship network connecting the top 25 collaborators of Ruth A. Duffy. A scholar is included among the top collaborators of Ruth A. Duffy based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ruth A. Duffy. Ruth A. Duffy is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Duffy, Ruth A.. (2024). Healthcare and the Troubles. Liverpool University Press eBooks. 1 indexed citations

Houwing, Natalie, Xiaofeng Wang, Heidi C. Waters, et al.. (2021). An Integrated Pharmacokinetic–Pharmacodynamic–Pharmacoeconomic Modeling Method to Evaluate Treatments for Adults with Schizophrenia. PharmacoEconomics. 40(1). 121–131. 3 indexed citations

Aigbogun, Myrlene Sanon, Martin Cloutier, Marjolaine Gauthier‐Loiselle, et al.. (2020). Real-World Treatment Patterns and Characteristics Among Patients with Agitation and Dementia in the United States: Findings from a Large, Observational, Retrospective Chart Review. Journal of Alzheimer s Disease. 77(3). 1181–1194. 16 indexed citations

Anatchkova, Milena, Ann Hartry, Ruth A. Duffy, et al.. (2019). Agitation in patients with dementia: a systematic review of epidemiology and association with severity and course. International Psychogeriatrics. 31(9). 1305–1318. 21 indexed citations

Weiss, Catherine, Emmanuelle Weiller, Ross A. Baker, et al.. (2018). The effects of brexpiprazole and aripiprazole on body weight as monotherapy in patients with schizophrenia and as adjunctive treatment in patients with major depressive disorder. International Clinical Psychopharmacology. 33(5). 255–260. 21 indexed citations

Correll, Christoph U., Catherine Weiss, Mary Hobart, et al.. (2018). Successful switching of patients with acute schizophrenia from another antipsychotic to brexpiprazole: comparison of clinicians’ choice of cross-titration schedules in a post hoc analysis of a randomized, double-blind, maintenance treatment study. CNS Spectrums. 24(5). 507–517. 13 indexed citations

Sussman, Matthew, Jeffrey Yu, Siddhesh Kamat, et al.. (2016). Cost-effectiveness of brexpiprazole adjunctive treatment for major depressive disorder. Journal of Affective Disorders. 207. 54–62. 8 indexed citations

Moore, K. T., et al.. (2009). Cloning, expression, and pharmacological characterization of the GPR120 free fatty acid receptor from cynomolgus monkey: Comparison with human GPR120 splice variants. Comparative Biochemistry and Physiology Part B Biochemistry and Molecular Biology. 154(4). 419–426. 57 indexed citations

Turpin, Graham, et al.. (2008). Mejorando el acceso a las terapias psicológicas: una iniciativa nacional para asegurar la prestación de terapias de alta calidad basadas en la evidencia. Papeles del Psicólogo - Psychologist Papers. 29(3). 271–280. 12 indexed citations

10.

Duffy, Ruth A.. (2004). Potential therapeutic targets for neurokinin-1 receptor antagonists. Expert Opinion on Emerging Drugs. 9(1). 9–21. 46 indexed citations

11.

McCombie, Stuart W., Jayaram R. Tagat, Dennis V. Nazareno, et al.. (2002). Synthesis and structure–Activity relationships of M2-Selective muscarinic receptor ligands in the 1-[4-(4-Arylsulfonyl)-phenylmethyl]-4-(4-piperidinyl)-piperazine family. Bioorganic & Medicinal Chemistry Letters. 12(5). 795–798. 8 indexed citations

12.

Duffy, Ruth A., Geoffrey B. Varty, Cynthia A. Morgan, & Jean E. Lachowicz. (2002). Correlation of Neurokinin (NK) 1 Receptor Occupancy in Gerbil Striatum with Behavioral Effects of NK1 Antagonists. Journal of Pharmacology and Experimental Therapeutics. 301(2). 536–542. 47 indexed citations

13.

Wang, Yuguang, Samuel Chackalamannil, Zhiyong Hu, et al.. (2002). Sulfide analogues as potent and selective M2 muscarinic receptor antagonists. Bioorganic & Medicinal Chemistry Letters. 12(7). 1087–1091. 6 indexed citations

14.

McLeod, Robbie L., Robert Aslanian, M. del Prado, et al.. (1998). Sch 50971, an Orally Active Histamine H3 Receptor Agonist, Inhibits Central Neurogenic Vascular Inflammation and Produces Sedation in the Guinea Pig. Journal of Pharmacology and Experimental Therapeutics. 287(1). 43–50. 44 indexed citations

15.

Taylor, Lisa A., et al.. (1994). Characterization of the binding of SCH 39166 to the five cloned dopamine receptor subtypes. Pharmacology Biochemistry and Behavior. 49(3). 567–571. 28 indexed citations

16.

Duffy, Ruth A., G Kamińska, Richard E. Chipkin, & Robert D. McQuade. (1992). Selective up-regulation of D-1 dopamine receptors following chronic administration of SCH 39166 in primates. Pharmacology Biochemistry and Behavior. 41(1). 235–238. 8 indexed citations

17.

Kozlowski, Joseph A., Derek Lowe, Henry Guzik, et al.. (1992). Dopamine receptor binding properties of some 2,3,4,5-tetrahydro-1H-3-benzazepine-7-ols with non-aromatic substituents in the 5-position. Bioorganic & Medicinal Chemistry Letters. 2(5). 399–402. 3 indexed citations

18.

McQuade, Robert D., Ruth A. Duffy, Vicki L. Coffin, & Allen Barnett. (1992). In vivo binding to dopamine receptors: a correlate of potential antipsychotic activity. European Journal of Pharmacology. 215(1). 29–34. 19 indexed citations

19.

McQuade, Richard, Ruth A. Duffy, Vicki L. Coffin, Richard E. Chipkin, & A Barnett. (1991). In vivo binding of SCH 39166: a D-1 selective antagonist.. Journal of Pharmacology and Experimental Therapeutics. 257(1). 42–49. 32 indexed citations

20.

McQuade, Robert D., Ruth A. Duffy, Gordon Crosby, et al.. (1991). [³H]SCH 39166, A New D₁‐Selective Radioligand: In Vitro and In Vivo Binding Analyses. Journal of Neurochemistry. 57(6). 2001–2010. 32 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact